CONMED Corp.
https://www.conmed.com/en
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From CONMED Corp.
Asia Deal Watch: Nippon Shinyaku Takes On Intractable Rare Disease With MiNA
Plus deals involving Incyte/CMS, Biocytogen/ABL, Bharat/Biofabri/Bilthoven, Dr. Reddy’s/Pharmazz, Veeda/Heads, Sosei Heptares/GSK, BioGeometry/Sanyou, Ono/Sibylla and Teijin/BioProjet
Project Orbis: More Cancer Drugs Available In Scotland Than England
The UK joined Project Orbis in 2021 with the aim of speeding up the regulatory process for promising cancer drugs, but fewer than half of the drugs licensed under this pathway are available on the NHS in England.
EU Must Adopt Innovative Drugs & AI ‘At Scale’ To Plug Cancer Care Gaps
European countries should establish “implementation budgets” to fund innovative cancer therapies and leverage technologies such as AI in drug R&D to meet the rising demand for cancer care, pharmaceutical industry representatives say.
GSK And Takeda Boost Arrowhead’s Coffers, But In-House Results Crucial To Gene Silencing Platform
Arrowhead is expecting a flurry of early-stage results from its in-house pipeline, including in lung diseases, where gene silencing platforms have so far struggled to reach, as it banks two recent milestone payments.
Company Information
- Industry
-
Medical Devices
- Monitoring Equipment & Devices
-
Surgical Equipment & Devices
- Minimally or Less Invasive
- Other Names / Subsidiaries
-
- Biorez, Inc.
- Buffalo Filter
- Concept, Inc.
- In2Bones Global
- SurgiQuest, Inc.
- Viking Systems
- Linvatec Corporation
- Bionx Implants Ltd.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice